Quality-by-design-engineered mitochondrial targeted nanoparticles for glioblastoma therapy
Open Access
- 23 October 2024
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (46) , 34100-34118
Abstract
Glioblastoma (GB, IDH-wildtype) constitutes the most aggressive primary malignant neoplasm with limited treatment modalities due to the blood–brain barrier (BBB) often restricting drug delivery. It also has an overall low survival rate with no curative solution, reinforcing the need for innovative formulation development for effective management of GB. This study explores a novel approach using triphenylphosphonium (TPP+)-conjugated chitosan nanoparticles for targeted mitochondrial delivery of temozolomide (TMZ) to GB cells. The conjugated nanoparticles were designed to leverage chitosan's biocompatibility and TPP's mitochondrial targeting ability. TMZ-loaded chitosan nanoparticles were systematically developed and optimized employing a Quality-by-Design (QbD) approach with a screening of factors (Taguchi design) followed by optimization (Box–Behnken design). The optimized nanoparticles had an average particle size of 138.1 ± 5 nm, PDI of 0.242 ± 0.04, and entrapment efficiency of 93.59 ± 3%. Further, a conjugate chitosan-TPP+ (CS-TPP+) was synthesized and validated, employing varied techniques such as NMR, FTIR, HPLC, zeta potential, and EDAX analysis. In vitro drug release in pH 5 phosphate buffer showed a sustained release for nanoparticulate formulations compared to the free drug solution further indicating that conjugation did not alter the release pattern of nanoparticles. With regards to intranasal delivery of the formulation, an ex vivo study carried out on goat nasal mucosa demonstrated greater retention of conjugated chitosan nanoparticles on nasal mucosa than free drug solution, and a mucin interaction study also corroborated this finding. In vitro cell line studies indicated nanoparticles' cytotoxic potential compared to TMZ solution. Overall, this study highlights the potential of TPP+-conjugated chitosan nanoparticles developed strategically for the targeted delivery of TMZ to mitochondria.Keywords
Funding Information
- Birla Institute of Technology and Science, Pilani
This publication has 52 references indexed in Scilit:
- A New Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) Method for Determination of Kinetin Riboside (Plant Hormone) in Dequalinium Chloride Based Self-assembled Vesicles: Development, Validation, and Force Degradation StudyChromatographia, 2023
- Preparation, physical properties, and evaluation of antioxidant capacity of aqueous grape extract loaded in chitosan‐TPP nanoparticlesFood Science & Nutrition, 2022
- Recent trends of bioconjugated nanomedicines through nose-to-brain delivery for neurological disordersDrug Delivery and Translational Research, 2022
- Mitochondria-targeted drug delivery in cancersBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020
- Formulation of Stattic as STAT3 inhibitor in nanostructured lipid carriers (NLCs) enhances efficacy of doxorubicin in melanoma cancer cellsNaunyn-Schmiedeberg's Archives of Pharmacology, 2020
- Novel controlled ionic gelation strategy for chitosan nanoparticles preparation using TPP-β-CD inclusion complexEuropean Journal of Pharmaceutical Sciences, 2018
- A general method for the separation of triphenylphosphine oxide and reaction products using high performance countercurrent chromatographyJournal of Chromatography A, 2014
- Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic StrategiesArchivum Immunologiae et Therapiae Experimentalis, 2012
- Epidemiology and etiology of gliomasActa Neuropathologica, 2005
- Likelihood of a model and information criteriaJournal of Econometrics, 1981